![](https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg)
Farxiga approved in the US for the treatment of paediatric type-2 diabetes
AstraZeneca’s Farxiga (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycaemic control in paediatric patients with type-2 diabetes (T2D) aged 10 years and older. The FDA approval was based on positive results from …